Fosun New Crown Vaccine Domestic Phase II Clinical Launch of China-Germany Vaccine Cooperation "Results"

It is worth mentioning that the vaccine overseas Phase III. Clinical results show that its effectiveness reached a staggering 95%, far exceeding expectations.
, Fosun and BioNTech partner Pfizer have applied for FDA Emergency Use Authorization (EUA) in the United States.
new crown outbreak spreads around the world, vaccine research and development along various technical routes is taking place at an ultra-high rate, competing with the virus for time.
the concerted efforts of countries around the world, the new crown vaccine research and development speed set a new record in the history of mankind's fight against infectious diseases.
as of November 12, at least 11 vaccine candidates worldwide have entered Phase III. Clinical trials, and several candidate vaccines have been mass-produced ahead of schedule, injecting a "strong needle" into countries around the world still shrouded in the outbreak.
contribution from China is indispensable in the global "boost".
's new crown vaccine is the product of a deep collaboration between Fosun and BioNTech, a German biotech company.
November 24, the leaders of China and Germany said in a telephone call that the two sides will strengthen vaccine exchanges and cooperation.
consensus, close industrial cooperation and joint efforts to combat the epidemic have become the main theme of china-Germany cooperation and exchanges.
As a model of China-Germany cooperation to promote the transformation of global scientific research results, Fosun New Crown Vaccine embodies the wisdom of Chinese scientific research and the innovative ability of the world's leading pharmaceutical companies, and is a representative mRNA nucleic acid vaccine in domestic vaccine research and development.
back to the early days of the outbreak, based on the accumulation of its own pharmaceutical industry and the global layout of science and technology, Fosun management quickly made a decision to lay out a new crown vaccine, the mRNA nucleic acid vaccine, through international cooperation on the new technology circuit.
Unlike traditional technical routes such as inactivated vaccines and viral vector vaccines, mRNA nucleic acid vaccine is a new type of nucleic acid vaccine that does not contain viral components, has no risk of infection, is more specific, has higher effectiveness, and has a faster research and development cycle and easy mass production to secure global supply.
March 13, Fosun Pharma became BioNTech's strategic partner in China, jointly developing and commercializing vaccine products for new coronavirus based on its proprietary mRNA technology platform in Chinese mainland and Hong Kong, Macao and Taiwan.
Since the cooperation between the two sides, Fosun Pharma has been deeply involved in the development of mRNA vaccines, in addition to fully and deeply exploring research and development plans with partners, completing clinical trials in China, and designing and completing animal drug testing of multiple mRNA selected vaccines, including BNT162b2, with Chinese research units, and sharing them with partners in a timely manner.
November 18, BioNTech announced the completion of a 95% global Phase III clinical trial of MRNA's new crown candidate vaccine BNT162b2, and on November 20 applied to the U.S. Food and Drug Administration (FDA) for approval of the Emergency Use Authorization (EUA) for the BNT162b2 vaccine.
At the same time, with the support of the Chinese government and relevant departments such as the State Drug Administration, Fosun Pharma has rapidly advanced clinical research on vaccines in China, accelerated the domestic market of highly effective mRNA nucleic acid vaccines, and provided critical clinical data for the widespread popularization and use of the vaccine in other countries and regions around the world.
new crown vaccine is just one example of China's active participation in international cooperation in vaccine research and development.
In fact, after the outbreak of the new crown, from the first time to announce the genome sequence of the new crown virus to the world, to the first release of vaccine clinical trial data, from the opening of all vaccine research and development technology routes, to join the "new crown pneumonia vaccine implementation plan", from the active participation of scientific and technical personnel in international research and development cooperation, to a number of enterprises to promote cross-border cooperation ... China continues to promote international cooperation in the development of new crown vaccines.
According to the joint prevention and control mechanism of the State Council of China, China's new crown vaccine research and development covers the inactivated vaccine, recombinant protein vaccine, adenovirus vector vaccine, anti-virus virus vector vaccine and nucleic acid vaccine and other five technical routes, have been in cooperation with many countries.
January 2020, China first publicly shared the virus's genetic sequence.
based on genetic sequence data, BioNTech in Germany has rapidly developed several candidate vaccines.
This year, facing the epidemic "big test", including Fosun, a number of Chinese private enterprises, including Fosun, effective use of global resources to complement each other, in vaccine research and development, production and promotion of good progress, in the world stage to show the strength and role of Chinese enterprises, set a global cooperation in vaccine research and development model, but also for mankind to finally overcome the new coronavirus brought the dawn.
。